Anne Bosy is a scientific researcher and innovator, and the inventor of the Oravital™ System. As Chief Scientist & Clinic Founder, Anne's uniquely successful science-based approach to the treatment of halitosis and periodontal disease is revolutionising the modern dental industry.
In addition to receiving her Dental Hygiene diploma and Master of Education degree at the University of Toronto, Anne became the first person to receive a research Master of Science degree specialising in Oral Malodour. Anne first gained international recognition as a result of her ground-breaking research proving that periodontally healthy individuals can suffer from advanced oral infections, and specifically chronic halitosis. In 1993 Anne founded the world's first dedicated halitosis clinic. As clinical director, she designed the medications and protocols that successfully treated thousands of patients who travelled to Toronto from more than 30 countries. The protocols used at the Fresh Breath Clinic became the Oravital™ System.
Today Anne Bosy is recognised internationally as a world-class expert in the field of oral health research.
Anne's focus on improving the delivery of oral healthcare has a robust history, and includes working on-site with the government of Barbados as the head of a two-year project which successfully restructured and greatly improved the island nation's dental program serving 250,000 people.
During her 30-year tenure as professor at George Brown College and several years at Regency Dental Hygiene Academy in Toronto, Anne trained generations of hygienists, designed several core programs, and was instrumental in the introduction of innovative teaching methods including the modular computer assisted teaching systems at the College.
Dr. Loesche received his BA degree from Yale University in 1957, his D.M.D. from Harvard, 1961, and his PhD from Massachusetts Institute of Technology in 1967. He is Professor of Dentistry, School of Dentistry, and Professor of Microbiology and Immunology, School of Medicine, University of Michigan. He was the Director for Research from 1987-1989 and initiated the student research dual between the University of Michigan Dental School and the Ohio State University Dental School. He is a past President of the American Association for Dental Research and has served on several NIH and FDA committees.
Currently he is active on the Taxonomic Subcommittee on Gram-negative Anaerobic Rods, and the International Dental Health Foundation. He is also serving on several journal editorial boards. He is the author of over 160 articles which have appeared in peer reviewed journals, over 40 invited reviews and chapters in books, and the author of two books and co-author of another.
Dr. Loesche is the recipient of many honors and awards including Dr. honoris causa, honorary degree awarded by the University of Turku, Finland; Dr. Odont - honorary degree awarded by University of Göteborg, Sweden; Rosenstat Visiting Professor in Health Sciences, University of Toronto; Doctor honoris causa, honorary degree awarded by the University of Ghent, Belgium; International Association for Dental Research Distinguished Scientist Award for research in dental caries, and a new species of gram-negative anaerobic rods isolated from the oral cavity named in recognition of his work, Prevotella loescheii.
His research has focused on the specific role of certain bacteria in dental caries and periodontal disease. In 1976 he used the concept of the Specific Plaque Hypothesis to develop diagnostic and treatment paradigms for the management of dental caries as a specific bacterial infection involving Streptococcus mutans and lactobacilli. Later the hypothesis was expanded to include the role of certain anaerobic bacteria in periodontal disease. He is currently the project director and principal investigator for a large NIH program project grant investigating the effects of oral health on medical outcomes. He is also the principal investigator on a longitudinal clinical study involving metronidazole in the treatment of periodontal disease.
Dr. Marvin Cohen, Co-Founder and Chairman of the Board of Triumph Pharmaceuticals, is the driving force behind education and resolution of bad breath. Dr. Cohen is recognized as a leading authority on the etiology, diagnosis and treatment of halitosis. He has published 13 research projects and lectured extensively in the United States, Canada and Europe.
Dr. Cohen had developed the revolutionary Zinc ion technology used in the Oravital™ SmartMouth mouthwash formulation. This patented system attacks bad breath in two ways: First, it eliminates any bad breath that already exists in your mouth. Second, its zinc ion technology neutralizes bacteria, preventing them from producing odourous chemicals for at least 12-hours after each rinse. Oravital Inc is the exclusive distributor of SmartMouth products in Canada and has integrated the Zinc ion technology into its revolutionary breath and oral infection treatment system.